Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA RhoB refers to small interfering RNA molecules designed to specifically target and silence the expression of the Ras homolog family member B (RhoB) gene. RhoB is a small GTPase that functions as a molecular switch in various cellular processes, including actin cytoskeleton organization, vesicle trafficking, and cell survival. In oncology, RhoB is often characterized as a stress-induced protein that can influence tumor cell migration, apoptosis, and response to chemotherapy or radiation. The therapeutic use of siRNA RhoB involves the incorporation of the double-stranded RNA into the RNA-induced silencing complex (RISC), leading to the sequence-specific cleavage of RhoB mRNA and subsequent reduction in RhoB protein levels. This approach is primarily investigated in preclinical models for its potential to sensitize tumors to treatment or inhibit metastatic progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siRNA RhoB.